Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must be ≥ 18 years of age~* Subjects must have documented diagnosis of multiple myeloma and have measurable disease~* Subjects must have undergone prior treatment with ≥ 2 treatment lines of anti-myeloma therapy~* Subjects must have either refractory or relapsed and refractory disease defined as documented disease progression during or within 60 days of completing their last myeloma therapy~* All subjects must have received at least 2 consecutive cycles of prior treatment that included lenalidomide and bortezomib~* All subjects must have failed treatment with both lenalidomide and bortezomib in one of the following ways: 1) Documented progressive disease on or within 60 days of completing treatment with lenalidomide and/or bortezomib, or 2) In case of prior response \[≥ partial response (PR)\] to lenalidomide or bortezomib, subjects must have relapsed within 6 months after stopping treatment with lenalidomide and/or bortezomib-containing regimens, or 3) Subjects who have not had a ≥ minimal response (MR) and have developed intolerance/toxicity after a minimum of two cycles of lenalidomide- and/or bortezomib-containing regimen~* Patients must have received adequate prior alkylator therapy~* Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2~* Females of childbearing potential (FCBP) must not become pregnant for 28 days prior to initiation of study drug, during the study, and for 28 days after discontinuation~* Females must agree to abstain from breastfeeding during study participation and 28 days after study drug discontinuation~* Males must agree to use a latex condom during any sexual during the study and for 28 days following discontinuation from this study~* Males must also agree to refrain from donating semen or sperm while on pomalidomide and for 28 days after discontinuation from this study~Exclusion Criteria:~* Any of the following laboratory abnormalities:~  * Absolute neutrophil count (ANC) \< 1,000/μL~ * Platelet count \< 75,000/ μL for subjects in whom \< 50% of bone marrow nucleated cells are plasma cells~ * Creatinine clearance \< 45 mL/min~ * Corrected serum calcium \> 14 mg/dL~ * Hemoglobin ≤ 8 g/dL~ * Serum glutamic oxaloacetic transaminase (SGOT)/ aspartate aminotransferase (AST) or transaminase, serum glutamic pyruvic (SGPT)/ alanine aminotransferase (ALT) \> 3.0 x upper limit of normal (ULN)~ * Serum total bilirubin \> 2.0 mg/dL~* Previous therapy with pomalidomide~* Hypersensitivity to thalidomide, lenalidomide, or dexamethasone~* Resistance to high-dose dexamethasone used in the last line of therapy~* Peripheral neuropathy ≥ Grade 2~* Subjects who received an allogeneic bone marrow or allogeneic peripheral blood stem cell transplant~* Subjects who are planning for or who are eligible for stem cell transplant~* Subjects with any one of the following: 1) Congestive heart failure, 2) Myocardial infarction within 12 months prior to starting study treatment, 3) Unstable or poorly controlled angina pectoris, including Prinzmetal variant angina pectoris~* Subjects who received any of the following within the last 14 days of initiation of study treatment: 1) Plasmapheresis, 2) Major surgery, 3) Radiation therapy, 4) Use of any anti-myeloma drug therapy~* Use of any investigational agents within 28 days or 5 half-lives (whichever is longer) of treatment~* Subjects with conditions requiring chronic steroid or immunosuppressive treatment~* Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study~* Incidence of gastrointestinal disease that may significantly alter the absorption of pomalidomide~* Subjects unable or unwilling to undergo antithrombotic prophylactic treatment~* Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subjects from signing the informed consent form~* Pregnant or breastfeeding females~* Known human immunodeficiency virus (HIV) positivity or active infectious hepatitis A, B, or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pomalidomide + Low-Dose Dexamethasone (Type: EXPERIMENTAL): Participants received 4 mg pomalidomide administered by mouth on Days 1 to 21 of each 28-day treatment cycle and 40 mg dexamethasone (or 20 mg for participants \> 75 years of age) administered by mouth once per day on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression.
- High-Dose Dexamethasone (Type: ACTIVE_COMPARATOR): Participants received 40 mg dexamethasone (or 20 mg for participants \> 75 years of age) administered by mouth once per day on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day treatment cycle until disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).